Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study

BACKGROUND: Taxane-containing adjuvant chemotherapy has been established as standard treatment in node-positive breast cancer. This study compared efficacy and tolerability of epirubicin (E)/cyclophosphamide (C) followed by docetaxel (Doc) with a dose-dense 5-fluorouracil (F)+E+ C regimen. METHODS:...

Descripción completa

Detalles Bibliográficos
Autores principales: Janni, W, Harbeck, N, Rack, B, Augustin, D, Jueckstock, J, Wischnik, A, Annecke, K, Scholz, C, Huober, J, Zwingers, T, Friedl, T W P, Kiechle, M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984804/
https://www.ncbi.nlm.nih.gov/pubmed/27031854
http://dx.doi.org/10.1038/bjc.2016.82

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4984804/
https://www.ncbi.nlm.nih.gov/pubmed/27031854
http://dx.doi.org/10.1038/bjc.2016.82

Ejemplares similares